SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-18-027095
Filing Date
2018-11-06
Accepted
2018-11-06 07:51:24
Documents
52
Period of Report
2018-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q atra-10q_20180930.htm 10-Q 1790017
2 EX-31.1 atra-ex311_12.htm EX-31.1 16130
3 EX-31.2 atra-ex312_11.htm EX-31.2 16155
4 EX-32.1 atra-ex321_9.htm EX-32.1 7425
  Complete submission text file 0001564590-18-027095.txt   5909060

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT atra-20180930.xml EX-101.INS 1275213
6 XBRL TAXONOMY EXTENSION SCHEMA atra-20180930.xsd EX-101.SCH 38275
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE atra-20180930_cal.xml EX-101.CAL 41383
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE atra-20180930_def.xml EX-101.DEF 128821
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE atra-20180930_lab.xml EX-101.LAB 324159
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE atra-20180930_pre.xml EX-101.PRE 237257
Mailing Address 611 GATEWAY BLVD SUITE 900 SOUTH SAN FRANCISCO CA 94080
Business Address 611 GATEWAY BLVD SUITE 900 SOUTH SAN FRANCISCO CA 94080 650-278-8930
Atara Biotherapeutics, Inc. (Filer) CIK: 0001604464 (see all company filings)

IRS No.: 460920988 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36548 | Film No.: 181161523
SIC: 2836 Biological Products, (No Diagnostic Substances)
Assistant Director 1